Sergio G. Garcia , Marta Clos-Sansalvador , Marta Sanroque-Muñoz , Linrong Pan , Marcella Franquesa
{"title":"间充质基质细胞-细胞外囊泡在肾脏疾病中的功能和效力测定","authors":"Sergio G. Garcia , Marta Clos-Sansalvador , Marta Sanroque-Muñoz , Linrong Pan , Marcella Franquesa","doi":"10.1016/j.cophys.2024.100746","DOIUrl":null,"url":null,"abstract":"<div><p>Kidney diseases pose a significant challenge, lacking effective therapies. Extracellular vesicle (EV)-based therapies have emerged as a novel advanced therapeutic. Particularly, mesenchymal stromal cells (MSC) and their EV are being explored as potential candidates. While MSC-EV therapeutics offer promise, there is a lack of widely standardized potency tests to assess EV effectiveness. Tailoring potency assessment in kidney diseases requires considering multifactorial effects and may necessitate a combination of multiple assays to recapitulate EV function. The design of a matrix of assays will be specific for the chosen disease and will involve specific molecular mechanisms and biological processes. This review highlights recent MSC-EV functional assays focused on modeling kidney disease mechanisms of action.</p></div>","PeriodicalId":52156,"journal":{"name":"Current Opinion in Physiology","volume":"38 ","pages":"Article 100746"},"PeriodicalIF":2.5000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Functional and potency assays for mesenchymal stromal cell–extracellular vesicles in kidney disease\",\"authors\":\"Sergio G. Garcia , Marta Clos-Sansalvador , Marta Sanroque-Muñoz , Linrong Pan , Marcella Franquesa\",\"doi\":\"10.1016/j.cophys.2024.100746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Kidney diseases pose a significant challenge, lacking effective therapies. Extracellular vesicle (EV)-based therapies have emerged as a novel advanced therapeutic. Particularly, mesenchymal stromal cells (MSC) and their EV are being explored as potential candidates. While MSC-EV therapeutics offer promise, there is a lack of widely standardized potency tests to assess EV effectiveness. Tailoring potency assessment in kidney diseases requires considering multifactorial effects and may necessitate a combination of multiple assays to recapitulate EV function. The design of a matrix of assays will be specific for the chosen disease and will involve specific molecular mechanisms and biological processes. This review highlights recent MSC-EV functional assays focused on modeling kidney disease mechanisms of action.</p></div>\",\"PeriodicalId\":52156,\"journal\":{\"name\":\"Current Opinion in Physiology\",\"volume\":\"38 \",\"pages\":\"Article 100746\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Physiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468867324000129\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHYSIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Physiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468867324000129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
Functional and potency assays for mesenchymal stromal cell–extracellular vesicles in kidney disease
Kidney diseases pose a significant challenge, lacking effective therapies. Extracellular vesicle (EV)-based therapies have emerged as a novel advanced therapeutic. Particularly, mesenchymal stromal cells (MSC) and their EV are being explored as potential candidates. While MSC-EV therapeutics offer promise, there is a lack of widely standardized potency tests to assess EV effectiveness. Tailoring potency assessment in kidney diseases requires considering multifactorial effects and may necessitate a combination of multiple assays to recapitulate EV function. The design of a matrix of assays will be specific for the chosen disease and will involve specific molecular mechanisms and biological processes. This review highlights recent MSC-EV functional assays focused on modeling kidney disease mechanisms of action.